{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T11:33:08Z","timestamp":1786793588475,"version":"build-2736575974"},"reference-count":265,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.intimp.2023.110331","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:01:02Z","timestamp":1684479662000},"page":"110331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Current and emerging prospects in the psoriatic treatment"],"prefix":"10.1016","volume":"120","author":[{"given":"Rutuja Vilas","family":"Nikam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gowtham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratiksha Sanjay","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja Sanjay","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110331_b0005","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jaad.2005.10.057","article-title":"Innate and adaptive immunity and the pathophysiology of psoriasis","volume":"54","author":"Gaspari","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2023.110331_b0010","doi-asserted-by":"crossref","first-page":"1085448","DOI":"10.3389\/fimmu.2023.1085448","article-title":"AIM2 and Psoriasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/247553031700200404","article-title":"Nail psoriasis: a review of treatment option","volume":"2","author":"Grinnell","year":"2017","journal-title":"J. Psoriasis and Psoriatic Arthritis"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/der2.91","article-title":"Psoriasis medications: the future","volume":"2","author":"Russo","year":"2021","journal-title":"Dermatol. Rev."},{"key":"10.1016\/j.intimp.2023.110331_b0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13020-018-0174-0","article-title":"Psoriasis therapy by Chinese medicine and modern agents","volume":"13","author":"Meng","year":"2018","journal-title":"Chin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0035","first-page":"11","article-title":"Psoriasis treatments: a review of the current research pipeline, psoriasis","volume":"17a","author":"Golant","year":"2011","journal-title":"Forum"},{"key":"10.1016\/j.intimp.2023.110331_b0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13671-020-00302-5","article-title":"JAK Inhibitors for psoriasis and psoriatic arthritis","volume":"9","author":"Varma","year":"2020","journal-title":"Curr. Dermatol. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/24755303211026023","article-title":"Identifying novel psoriatic disease drug targets using a genetics-based priority index pipeline","volume":"6","author":"Bui","year":"2021","journal-title":"J. Psoriasis and Psoriatic Arthritis"},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/2475530319826568","article-title":"Efficacy of biosimilars in psoriasis","volume":"4","author":"Tyutyunik","year":"2019","journal-title":"J. Psoriasis Psoriatic and Arthritis"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0060","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/keab606","article-title":"CICERO, The burden of psoriasis in patients with early psoriatic arthritis","volume":"61","author":"Kasiem","year":"2022","journal-title":"Rheumatol. (Oxford)"},{"key":"10.1016\/j.intimp.2023.110331_b0065","doi-asserted-by":"crossref","first-page":"adv00699","DOI":"10.2340\/actadv.v102.1991","article-title":"Sleep disorders and psoriasis: an update","volume":"102","author":"Halioua","year":"2022","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/2475530320964781","article-title":"Sleep and the gut microbiome in psoriasis: clinical implications for disease progression and the development of cardiometabolic comorbidities","volume":"6","author":"Myers","year":"2021","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"issue":"8","key":"10.1016\/j.intimp.2023.110331_b0075","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Meglio","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0080","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4081\/dr.2014.5451","article-title":"Progress in psoriasis therapy via novel drug delivery systems","volume":"6","author":"Vincent","year":"2014","journal-title":"Dermatol Reports."},{"issue":"10","key":"10.1016\/j.intimp.2023.110331_b0085","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/17425247.2016.1188801","article-title":"Current challenges and emerging drug delivery strategies for the treatment of psoriasis","volume":"13","author":"Hoffman","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2133.1995.tb05019.x","article-title":"The effect of severe psoriasis on the quality of life of 369 patients, 1995","volume":"132","author":"Finlay","year":"1995","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/135910539700200409","article-title":"The physical, psychological and social impact of psoriasis","volume":"2","author":"Rapp","year":"1997","journal-title":"J. Health Psychol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2023.110331_b0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","article-title":"Psoriasis: Is the impairment to a patient\u2019s life cumulative?","volume":"24","author":"Kimball","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"17","author":"Lebwohl","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2023.110331_b0115","doi-asserted-by":"crossref","first-page":"e44932","DOI":"10.2196\/44932","article-title":"Artificial intelligence-based psoriasis severity assessment: real-world study and application","volume":"25","author":"Huang","year":"2023","journal-title":"J. Med. Internet. Res."},{"issue":"19","key":"10.1016\/j.intimp.2023.110331_b0120","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0125","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.rdc.2015.07.013","article-title":"Etiology and pathogenesis of psoriasis","volume":"41","author":"Boehncke","year":"2015","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.intimp.2023.110331_b0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.intimp.2023.110331_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0378-6323.115505","article-title":"Pathophysiology of psoriasis","volume":"79","author":"Mahajan","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110331_b0140","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jid.2022.01.014","article-title":"From empirical to pathogenesis-based treatments for psoriasis","volume":"142","author":"van de Kerkhof","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2023.110331_b0145","first-page":"42","article-title":"Pathogenesis of psoriasis","volume":"15","author":"Mashhood","year":"2004","journal-title":"J. Pak. Assoc. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-\u03b1 production","volume":"202","author":"Nestle","year":"2005","journal-title":"J. Exp. Med."},{"issue":"20","key":"10.1016\/j.intimp.2023.110331_b0155","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0160","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.sder.2010.03.001","article-title":"New insights in the immunologic basis of psoriasis","volume":"29","author":"Nograles","year":"2010","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.intimp.2023.110331_b0170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.yadr.2008.09.006","article-title":"Update on the natural history and systemic treatment of psoriasis","volume":"24","author":"Richardson","year":"2008","journal-title":"Adv. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Hum. Genet."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b0180","first-page":"176","article-title":"The genetics of psoriasis\u2013selected novelties in 2008","volume":"17","author":"Pasi\u0107","year":"2009","journal-title":"Acta Dermatovenerol. Croat."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0185","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1086\/303075","article-title":"Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13","volume":"67","author":"Lee","year":"2000","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jmg.38.1.7","article-title":"Original articles Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci","volume":"38","author":"Veal","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.intimp.2023.110331_b0195","doi-asserted-by":"crossref","unstructured":"U. H\u00fcffmeier, J. Lascorz, T. Becker, F. Sch\u00fcrmeier-Horst, A. Magener A, A. B. Ekici, S. Endele, C. T. Thiel, S. Thoma-Uszynski, R. M\u00f6ssner, K. Reich, W. Kurrat, T.F. Wienker, H. Traupe, A. Reis, Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1, J Med Genet. 46(11) (2009) 736\u201344. 10.1136\/jmg.2008.065029.","DOI":"10.1136\/jmg.2008.065029"},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0200","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1046\/j.1523-1747.2002.19612.x","article-title":"Evidence for a major psoriasis susceptibility locus at 6p21 (PSORS1) and a novel candidate region at 4q31 by genome-wide scan in chinese hans","volume":"119","author":"Zhang","year":"2002","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b0205","doi-asserted-by":"crossref","first-page":"adv00032","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.25259\/IJDVL_1200_2021","article-title":"Psoriasis: from antiquity to the present","volume":"89","author":"Olejnik","year":"2023","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"8","key":"10.1016\/j.intimp.2023.110331_b0215","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.3390\/ijms23084457","article-title":"Psoriasis and systemic inflammatory disorders","volume":"23","author":"Tashiro","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.110331_b0220","article-title":"Promising new treatments for psoriasis","author":"Declercq","year":"2013","journal-title":"ScientificWorldJ."},{"key":"10.1016\/j.intimp.2023.110331_b0225","first-page":"4617520","article-title":"Successful treatment of plaque psoriasis with allogeneic gingival mesenchymal stem cells: a case study","author":"Wang","year":"2020","journal-title":"Case Rep Dermatol Med."},{"key":"10.1016\/j.intimp.2023.110331_b0230","doi-asserted-by":"crossref","unstructured":"J.G. Krueger, The immunologic basis for the treatment of psoriasis with new biologic agents, J Am Acad Dermatol 46(1) (2002) 1-23; quiz 23-26. 10.1067\/mjd.2002.120568.","DOI":"10.1067\/mjd.2002.120568"},{"key":"10.1016\/j.intimp.2023.110331_b0235","first-page":"39","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0240","first-page":"363","article-title":"Current developments and perspectives in psoriasis","volume":"21","author":"Sch\u00f6n","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0245","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1517\/14728214.10.1.35","article-title":"Emerging drugs for moderate-to-severe psoriasis","volume":"10","author":"Magliocco","year":"2005","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"12","key":"10.1016\/j.intimp.2023.110331_b0250","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s10067-016-3427-2","article-title":"Differentiating biosimilarity and comparability in biotherapeutics","volume":"35","author":"Azevedo","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110331_b0255","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/14712598.2019.1636963","article-title":"Biosimilars for the treatment of psoriasis","volume":"19","author":"Puig","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0260","first-page":"100","article-title":"Biologicals in psoriasis","volume":"18","author":"Mehta","year":"2008","journal-title":"J. Pak. Assoc. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0265","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0270","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/09546634.2012.672706","article-title":"Intralesional therapy for psoriasis","volume":"24","author":"Wang","year":"2013","journal-title":"J. Dermatol. Treat."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0275","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/09546634.2017.1398393","article-title":"Drug survival of biologic treatments in psoriasis: a systematic review","volume":"29","author":"No","year":"2018","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.intimp.2023.110331_b0280","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0285","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1529-8019.2008.00180.x","article-title":"DERMATOLOGIC THERAPY from conventional to cutting edge: the new era of biologics in treatment of psoriasis","volume":"21","author":"Ulia","year":"2008","journal-title":"Dermatol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0290","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1586\/14737167.4.5.573","article-title":"Management and costs of severe psoriasis: the role of new biologics","volume":"4","author":"Feldman","year":"2004","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0295","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2023.110331_b0300","unstructured":"U.S. Food and Drug Administration, AMEVIVE\u00ae (alefacept). label (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0305","unstructured":"U.S. Food and Drug Administration, RAPTIVA\u00ae [efalizumab]. label (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0310","unstructured":"U.S. Food and Drug Administration, Enbrel\u00ae (etanercept). Enbrel (etanercept) Label (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0315","unstructured":"National Psoriasis Foundation, Enbrel. Treating Psoriasis and Psoriatic Arthritis with Enbrel: National Psoriasis Foundation, (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0320","unstructured":"U.S. Food and Drug Administration, REMICADE (infliximab). REMICADE (infliximab) Label (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0325","unstructured":"National Psoriasis Foundation, Remicade. Treating Psoriasis and Psoriatic Arthritis with Remicade : National Psoriasis Foundation, (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0330","unstructured":"U.S. Food and Drug Administration, HUM IRA (adalimumab). Humira (adalimumab) label (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0335","unstructured":"National Psoriasis Foundation, Humira. Treating Psoriasis and Psoriatic Arthritis with Humira : National Psoriasis Foundation,(accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0340","unstructured":"National Psoriasis Foundation,Simponi. Treating Psoriasis and Psoriatic Arthritis with Simponi: National Psoriasis Foundation, (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0345","unstructured":"U.S. Food and Drug Administration, SIMPONI (gollmumab). Simponi (golimumab) label (fda.gov),(accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0350","unstructured":"U.S. Food and Drug Administration, CIMZIA (certolizumab pegol). Label: CIMZIA (certolizumab pegol) (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0355","unstructured":"National Psoriasis Foundation, FDA Approves Cimzia for Plaque Psoriasis. FDA approves Cimzia for plaque psoriasis: National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0360","unstructured":"National Psoriasis Foundation, Siliq (brodalumab). Treating Plaque Psoriasis with SILIQ: National Psoriasis Foundation, (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0365","unstructured":"U.S. Food and Drug Administration, SILIQ\u2122 (brodalumab). Siliq (brodalumab) Label (fda.gov),(accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0370","unstructured":"U.S. Food and Drug Administration, FDA approves new psoriasis drug. FDA approves new psoriasis drug | FDA, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0375","unstructured":"U.S. Food and Drug Administration, Drug Trials Snapshots. Drug Trials Snapshots: TALTZ | FDA, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0380","unstructured":"National Psoriasis Foundation, Taltz (ixekizumab). Taltz for Psoriasis and Psoriatic Arthritis: National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0385","unstructured":"U.S. Food and Drug Administration, COSENTYX\u00ae (secukinumab). label (fda.gov), (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0390","unstructured":"National Psoriasis Foundation, FDA Approves Cosentyx for Pediatric Patients. FDA Approves Cosentyx for Pediatric Patients : National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0395","unstructured":"National Psoriasis Foundation, Pediatric PsA Treatment Approval. Pediatric PsA Treatment Approval : National Psoriasis Foundation, (accessed 19 February 2023)."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0400","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"ERASURE Study Group; FIXTURE Study Group, Secukinumab in Plaque Psoriasis \u2014 Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110331_b0405","unstructured":"U.S. Food and Drug Administration, ILUMYA\u2122 (tildrakizumab-asmn). label (fda.gov), (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0410","unstructured":"National Psoriasis Foundation, Ilumya. Treating Plaque Psoriasis with Ilumya: National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0415","unstructured":"U.S. Food and Drug Administration, Drug trials Snapshots: ILUMYA. Drug Trials Snapshots: ILUMYA | FDA."},{"key":"10.1016\/j.intimp.2023.110331_b0420","unstructured":"National Psoriasis Foundation, Tremfya. Tremfya for Plaque Psoriasis and Psoriatic Arthritis Treatment : National Psoriasis Foundation, (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0425","unstructured":"U.S. Food and Drug Administration, TREMFYA (guselkumab). LABEL (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0430","unstructured":"U.S. Food and Drug Administration, SKYRIZI\u00ae (risankizumab-rzaa). label (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0435","unstructured":"National Psoriasis Foundation, Second SKYRIZI\u00ae Indication Approved. Second SKYRIZI\u00ae Indication Approved: National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0440","unstructured":"U.S. Food and Drug Administration, STELARA\u00ae (ustekinumab). STELARA\u00ae (ustekinumab) injection, for subcutaneous or intravenous (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0445","unstructured":"National Psoriasis Foundation, Stelara. Treating Psoriasis and Psoriatic Arthritis with Stelara: National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0450","unstructured":"National Psoriasis Foundation, FDA Approves Stelara\u00ae for Pediatric Psoriasis Patients. FDA Approves Stelara for Pediatric Psoriasis Patients: National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0455","unstructured":"National Psoriasis Foundation, FDA Approves SPEVIGO\u00ae for Adults with GPP. FDA Approves SPEVIGO\u00ae for Adults with GPP : National Psoriasis Foundation, (accessed 19 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0460","unstructured":"U.S. Food and Drug Administration, SPEVIGO\u00ae (spesolimab-sbzo). label (fda.gov), (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0465","unstructured":"U.S. Food and Drug Administration, AMEVIVE\u00ae (alefacept). Amevive (fda.gov),2005 (accessed 19 February 2023)."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0470","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1517\/14740338.4.6.975","article-title":"Alefacept: a safety profile","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.intimp.2023.110331_b0475","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0151-9638(06)70989-9","article-title":"Efalizumab","volume":"133","author":"Descamps","year":"2006","journal-title":"Ann. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0480","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.coph.2007.06.002","article-title":"Developments in systemic immunomodulatory therapy for psoriasis","volume":"7","author":"Berger","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110331_b0485","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u2013. Efalizumab. 2018 Feb 10. PMID: 31644098."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0490","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","article-title":"Mechanisms of action of etanercept in psoriasis","volume":"12","author":"Tan","year":"2007","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"10.1016\/j.intimp.2023.110331_b0495","first-page":"77","article-title":"Etanercept in the treatment of plaque psoriasis, Clin Cosmet Investig Dermatol","author":"Nguyen","year":"2009","journal-title":"May 2"},{"issue":"Suppl 7","key":"10.1016\/j.intimp.2023.110331_b0500","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.4103\/0378-6323.115526","article-title":"Tumor necrosis factor-\u03b1 antagonists: Side effects and their management","volume":"79","author":"Dogra","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0505","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2147\/TCRM.S3094","article-title":"Treatment of severe psoriasis with infliximab","volume":"4","author":"Leman","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.intimp.2023.110331_b0510","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/DDDT.S200147","article-title":"Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events","volume":"13","author":"Subedi","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0515","first-page":"345","article-title":"Gordon Treating psoriasis with adalimumab","volume":"4","author":"Alwawi","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"18","key":"10.1016\/j.intimp.2023.110331_b0520","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s40265-015-0503-x","article-title":"Adalimumab: a review in chronic plaque psoriasis","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2023.110331_b0525","unstructured":"C.R. Ellis, C.E. Azmat. Adalimumab. [Updated 2022 Dec 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-."},{"issue":"sup1","key":"10.1016\/j.intimp.2023.110331_b0530","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0535","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0540","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5021\/ad.2015.27.4.446","article-title":"Erythrodermic psoriasis treated with golimumab: a case report","volume":"27","author":"Lee","year":"2015","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.intimp.2023.110331_b0545","unstructured":"I.S. Padda, R. Bhatt, M Parmar. Golimumab. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan\u2013."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0550","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13555-017-0208-z","article-title":"Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: preliminary real-life data","volume":"7","author":"Dattola","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0555","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.clinthera.2009.06.015","article-title":"Certolizumab pegol for the management of Crohn's disease in adults","volume":"31","author":"Rivkin","year":"2009","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0560","first-page":"1","article-title":"Brodalumab: a review of safety","volume":"23","author":"Rusta-Sallehy","year":"2018","journal-title":"Skin Therapy Lett."},{"key":"10.1016\/j.intimp.2023.110331_b0565","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/DDDT.S113683","article-title":"Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy","volume":"11","author":"Roman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0570","unstructured":"N.M. Golbari, B.M. Basehore, P.M. Zito. Brodalumab. [Updated 2023 Mar 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0575","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","article-title":"Ixekizumab, citrate-free formulation: results from two clinical trials","volume":"39","author":"Chabra","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0580","unstructured":"U.S. Food and Drug Administration, TALTZ (ixekizumab). label (fda.gov), (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0585","unstructured":"C.V. Preuss, J. Quick. Ixekizumab. [Updated 2022 Sep 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-."},{"key":"10.1016\/j.intimp.2023.110331_b0590","unstructured":"S. Aboobacker, H. Kurn, A.M. Al Aboud. Secukinumab. [Updated 2022 Jul 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-."},{"key":"10.1016\/j.intimp.2023.110331_b0595","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/imt-2018-0028","article-title":"Tildrakizumab for the treatment of psoriasis","volume":"10","author":"Bangert","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2023.110331_b0600","first-page":"49","article-title":"Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date","volume":"8","author":"Beck","year":"2018","journal-title":"Psoriasis (Auckl)"},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0605","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatol. (Oxford)"},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0610","doi-asserted-by":"crossref","first-page":"e14857","DOI":"10.1111\/dth.14857","article-title":"Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review","volume":"34","author":"Camela","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2023.110331_b0615","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17512433.2019.1657829","article-title":"Risankizumab for the treatment of psoriasis","volume":"12","author":"Gu","year":"2019","journal-title":"Expert Rev. Clin. Pharmamcol."},{"key":"10.1016\/j.intimp.2023.110331_b0620","doi-asserted-by":"crossref","unstructured":"O. Cingoz, Ustekinumab, MAbs. 1(3) 216\u2013221. 10.4161\/mabs.1.3.8593.","DOI":"10.4161\/mabs.1.3.8593"},{"issue":"8","key":"10.1016\/j.intimp.2023.110331_b0625","first-page":"e9812","article-title":"FDA approved biologics: can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric\/adolescents in moderate to severe psoriasis?","volume":"12","author":"Aslam","year":"2020","journal-title":"A Systematic Rev. Cureus."},{"key":"10.1016\/j.intimp.2023.110331_b0630","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/PHMT.S75836","article-title":"Efficacy and safety of ustekinumab in adolescents","volume":"7","author":"Kellen","year":"2016","journal-title":"Pediatric Health Med Ther."},{"issue":"17","key":"10.1016\/j.intimp.2023.110331_b0635","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2023.110331_b0640","first-page":"161","article-title":"Biosimilars: science","volume":"16","author":"Batran","year":"2022","journal-title":"Implications, and Potential Outlooks in the Middle East and Africa, Biologics."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0645","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cpt.2761","article-title":"Pharmacodynamic biomarkers evidentiary considerations for biosimilar development and approval","volume":"113","author":"Strauss","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0650","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","article-title":"Biosimilar drugs for psoriasis: principles, present, and near future","volume":"8","author":"Carrascosa","year":"2018","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0655","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bcp.12656","article-title":"Biosimilar: what it is not","volume":"80","author":"de Mora","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0660","first-page":"270","volume":"38","author":"Ventola","year":"2013","journal-title":"Biosimilars: part 1: proposed regulatory criteria for FDA approval"},{"key":"10.1016\/j.intimp.2023.110331_b0665","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/2475530319826568","article-title":"Efficacy of Biosimilars in Psoriasis","volume":"4","author":"Tyutyunik","year":"2019","journal-title":"J. Psoriasis Psoriatic Arthritis."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0670","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/14740338.2020.1737674","article-title":"Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies?","volume":"19","author":"Reynolds","year":"2020","journal-title":"A rev. Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0675","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/09546631003763942","article-title":"Biosimilars: the \u201cfuture\u201d of biologic therapy?","volume":"22","author":"Ranjan","year":"2011","journal-title":"J. Dermatolog. Treat."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0680","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bcpt.13719","article-title":"Biosimilar, so it looks alike, but what does it mean?","volume":"130","author":"Varma","year":"2022","journal-title":"A qualitative study of Danish patients' perceptions of biosimilars, Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2023.110331_b0685","unstructured":"U.S. Food and Drug Administration, Biosimilar Product Information. Biosimilar Product Information | FDA, (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0690","unstructured":"National Psoriasis Foundation, AMJEVITATM for Psoriasis and PsA. AMJEVITA\u2122 for Psoriasis and PsA: National Psoriasis Foundation, (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0695","unstructured":"U.S. Food and Drug Administration, FDA Approves Amjevita, a biosimilar to humira. FDA approves Amjevita, a biosimilar to Humira | FDA, (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0700","unstructured":"U.S. Food and Drug Administration, AMJEVITA (adalimumab-atto). AMJEVITA (adalimumab-atto) injection for subcutaneous use Label (fda.gov), (accessed 20 February 2023)."},{"issue":"10","key":"10.1016\/j.intimp.2023.110331_b0705","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","article-title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.110331_b0710","unstructured":"U.S. Food and Drug Administration, FDA Approves Cyltezo. The First Interchangeable Biosimilar to Humira. FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira | FDA, (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0715","unstructured":"U.S. Food and Drug Administration, CYLTEZO\u00ae (adalimumab-adbm). label (fda.gov), (accessed 20 February 2023)."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0720","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40257-022-00708-w","article-title":"Switching between adalimumab reference product and BI 695501 in patients with chronic plaque psoriasis (VOLTAIRE-X): a randomized controlled trial","volume":"23","author":"Menter","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2023.110331_b0725","unstructured":"U.S. Food and Drug Administration, HADLIMA (adalimumab-bwwd). label (fda.gov), (accessed 20 February 2023)."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0730","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40259-018-0307-0","article-title":"SB5: an adalimumab biosimilar","volume":"32","author":"Frampton","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2023.110331_b0735","article-title":"Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110331_b0740","unstructured":"U.S. Food and Drug Administration, HYRIMOZ (adalimumab-adaz). label (fda.gov), (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0745","unstructured":"U.S. Food and Drug Administration, ABRILADA\u2122 (adalimumab-afzb). label (fda.gov), (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0750","unstructured":"U.S. Food and Drug Administration, HULIO\u00ae (adalimumab-fkjp). LABEL (fda.gov), (accessed 20 February 2023)."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b0755","doi-asserted-by":"crossref","first-page":"e00604","DOI":"10.1002\/prp2.604","article-title":"Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab","volume":"8","author":"Schreiber","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.intimp.2023.110331_b0760","unstructured":"U.S. Food and Drug Administration, IDACIO\u00ae (adalimumab-aacf). label (fda.gov), (accessed 20 February 2023)."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0765","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40744-022-00432-1","article-title":"A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar MSB11022 delivered via autoinjector and pre-filled syringe in healthy subjects","volume":"9","author":"Sabet","year":"2022","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0770","unstructured":"U.S. Food and Drug Administration, Biosimilar Multidisciplinary Evaluation and Review (BMER) {BLA 761216} CHS-1420, a proposed biosimilar to U.S.-Humira. Biosimilar Multidisciplinary Evaluation and Review (Yusimry) (fda.gov), (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0775","unstructured":"U.S. Food and Drug Administration, YUSIMRY (adalimumab-aqvh). label (fda.gov), (accessed 20 February 2023)."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0780","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","article-title":"Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity","volume":"8","author":"Huizinga","year":"2021","journal-title":"Rheumatol Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0785","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40259-019-00335-8","article-title":"FKB327: an adalimumab biosimilar","volume":"33","author":"Al-Salama","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2023.110331_b0790","unstructured":"National Psoriasis Foundation, Biosimilars. Biosimilars for Psoriasis : National Psoriasis Foundation, (accessed 25 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0795","unstructured":"U.S. Food and Drug Administration, Eticovo (etanercept-ykro). LABEL (fda.gov), (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0800","article-title":"Safety and effectiveness of etanercept biosimilar SB4 for rheumatic diseases in south korea: real-world post-marketing surveillance data","author":"Yoo","year":"2022","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0805","unstructured":"U.S. Food and Drug Administration, ERELZI (etanercept-szzs). ERELZI (etanercept-szzs) injection (fda.gov), (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0810","first-page":"116","article-title":"Biosimilars in psoriasis: the future or not?","volume":"99","author":"Kellen","year":"2017","journal-title":"Cutis"},{"key":"10.1016\/j.intimp.2023.110331_b0815","unstructured":"U.S. Food and Drug Administration, INFLECTRA (infliximab-dyyb). label (fda.gov), (accessed 20 February 2023)."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b0820","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40259-014-0094-1","article-title":"A review of CT-P13: an infliximab biosimilar","volume":"28","author":"McKeage","year":"2014","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0825","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14712598.2021.1958778","article-title":"A Systematic review on infliximab biosimilar SB2: from pre-clinical data to real-world evidence","volume":"22","author":"Macaluso","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0830","unstructured":"U.S. Food and Drug Administration, RENFLEXIS (infliximab-abda). 761054Orig1s000lbledt.pdf (fda.gov), (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0835","unstructured":"U.S. Food and Drug Administration, IXIFI (infliximab-qbtx). label (fda.gov), (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0840","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12325-021-01944-y","article-title":"A review of the totality of evidence for the development and approval of ABP 710 (AVSOLA), an infliximab biosimilar","volume":"39","author":"Reinisch","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0845","unstructured":"U.S. Food and Drug Administration, AVSOLA (infliximab-axxq). label (fda.gov), (accessed 20 February 2023)."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b0850","first-page":"169","article-title":"The efficacy and safety of the biosimilar product (Inflectra\u00ae) compared to the reference drug (Remicade\u00ae) in rescue therapy in adult patients with ulcerative colitis","volume":"12","author":"Kaniewska","year":"2017","journal-title":"Prz Gastroenterol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0855","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40259-018-0310-5","article-title":"PF-06438179\/GP1111: an infliximab biosimilar","volume":"32","author":"Al-Salama","year":"2018","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0860","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12325-021-01944-y","article-title":"A review of the totality of evidence for the development and approval of ABP 710 (AVSOLA), an Infliximab Biosimilar","volume":"39","author":"Reinisch","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.intimp.2023.110331_b0865","doi-asserted-by":"crossref","unstructured":"F.C. Eberle, J. Br\u00fcck, J. Holstein, K. Hirahara, K. Ghoreschi, Recent advances in understanding psoriasis, [version 1; referees: 2 approved] F1000Res. 2016 5(F1000 Faculty Rev):770. doi: 10.12688\/f1000research.7927.1.","DOI":"10.12688\/f1000research.7927.1"},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/idoj.IDOJ_437_18","article-title":"Apremilast in psoriasis and beyond: Big hopes on a small molecule","volume":"10","author":"Afra","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.intimp.2023.110331_b0875","first-page":"231","article-title":"Towards personalized medicine in psoriasis: current progress","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis (Auckl)"},{"issue":"18","key":"10.1016\/j.intimp.2023.110331_b0880","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/14656566.2017.1409205","article-title":"Advances in treating psoriasis in the elderly with small molecule inhibitors","volume":"18","author":"Cline","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0885","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/1346-8138.15727","article-title":"Psoriasis: recent progress in molecular-targeted therapies","volume":"48","author":"Honma","year":"2021","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0890","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2022.22.e9","article-title":"Targeted immunotherapy for autoimmune diseas","volume":"22","author":"Jung","year":"2022","journal-title":"Immune Netw."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0895","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2340\/00015555-1931","article-title":"New drugs and treatment targets in psoriasis","volume":"95","author":"Kofoed","year":"2015","journal-title":"Acta Derm. Venereol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b0900","first-page":"101","article-title":"New Treatments for psoriasis: an update on a therapeutic frontier","volume":"111","author":"Del","year":"2023","journal-title":"Cutis"},{"key":"10.1016\/j.intimp.2023.110331_b0905","unstructured":"U.S. Food and Drug Administration, OTEZLA\u00ae (apremilast). OTEZLA (apremilast) Label (fda.gov), (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0910","unstructured":"U.S. Food and Drug Administration, ZORYVE\u2122 (roflumilast). label (fda.gov), (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0915","unstructured":"U.S. Food and Drug Administration, XELJANZ\u00ae (tofacitinib). XELJANZ (tofacitinib) (fda.gov), (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0920","unstructured":"U.S. Food and Drug Administration, SOTYKTU\u2122 (deucravacitinib). label (fda.gov), (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0925","unstructured":"U.S. Food and Drug Administration, VTAMA (tapinarof). label (fda.gov), (accessed 26 April 2023)."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b0930","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","article-title":"Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast","volume":"29","author":"Gooderham","year":"2015","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0935","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-013-0023-0","article-title":"Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases","volume":"3","author":"Wittmann","year":"2013","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.intimp.2023.110331_b0940","first-page":"21","volume":"11","author":"Milakovic","year":"2021","journal-title":"Phosphodiesterase-4 Inhibition in Psoriasis Psoriasis (Auckl)"},{"issue":"11","key":"10.1016\/j.intimp.2023.110331_b0945","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4155\/bio-2018-0004","article-title":"Determination of a PDE4 inhibitor Hemay 005 in human plasma and urine by UPLC-MS\/MS and its application to a PK study","volume":"10","author":"Liu","year":"2018","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0950","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2023.110331_b0955","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110331_b0960","unstructured":"U.S. Food and Drug Administration, FDA Approves First Oral Treatment for Psoriasis Severities. FDA Approves First Oral Treatment for All Psoriasis Severities : National Psoriasis Foundation, (accessed 26 April 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0965","unstructured":"National Psoriasis Foundation, FDA Approves ZORYVE\u2122 Cream for Adolescent and Adults. FDA Approves ZORYVE\u2122 Cream for Adolescents and Adults: National Psoriasis Foundation, (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b0970","article-title":"A review of topical roflumilast for the treatment of plaque psoriasis","volume":"10600280221137750","author":"Pixley","year":"2022","journal-title":"Ann. Pharmacother."},{"issue":"9","key":"10.1016\/j.intimp.2023.110331_b0975","article-title":"Novel therapeutic target(s) for psoriatic disease","volume":"21","author":"Thakur","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b0980","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b0985","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK Inhibitors: a review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"11","key":"10.1016\/j.intimp.2023.110331_b0990","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1248\/bpb.b21-00609","article-title":"Therapeutic advantage of Tyk2 inhibition for treating autoimmune and chronic inflammatory diseases","volume":"44","author":"Muromoto","year":"2021","journal-title":"Biol. Pharm. Bull."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b0995","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.110331_b1000","unstructured":"National Psoriasis Foundation, FDA Approves Sotyktu \u2122 for Psoriasis. FDA Approves Sotyktu\u2122 for Psoriasis: National Psoriasis Foundation, (accessed 20 February 2023)."},{"issue":"17","key":"10.1016\/j.intimp.2023.110331_b1005","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.intimp.2023.110331_b1010","first-page":"1671","article-title":"Deucravacitinib in the treatment of psoriasis","volume":"82","author":"Estevinho","year":"2022","journal-title":"J. Dermatol. Treat."},{"issue":"12","key":"10.1016\/j.intimp.2023.110331_b1015","first-page":"28","article-title":"New and emerging topical therapies for psoriasis and atopic dermatitis","volume":"12","author":"Psomadakis","year":"2019","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.intimp.2023.110331_b1020","unstructured":"National Psoriasis Foundation, FDA Approves VTAMA\u00ae.FDA Approves VTAMA\u00ae for Adults with Psoriasis: National Psoriasis Foundation, (accessed 20 February 2023)."},{"key":"10.1016\/j.intimp.2023.110331_b1025","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110331_b1030","doi-asserted-by":"crossref","first-page":"1159453","DOI":"10.3389\/fmed.2023.1159453","article-title":"Drug repositioning prediction for psoriasis using the adverse event reporting database","volume":"23","author":"Ko","year":"2023","journal-title":"Front Med. (Lausanne)"},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b1035","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/jcp.29413","article-title":"Repurposing an old drug for new use: niclosamide in psoriasis-like skin inflammation","volume":"235","author":"Thatikonda","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2023.110331_b1040","doi-asserted-by":"crossref","unstructured":"H.S. Gns, S. GR, M. Murahari, M. Krishnamurthy. An update on Drug Repurposing: Re-written saga of the drug\u2019s fate, Biomed Pharmacother. 110 2019 700\u2013716. 10.1016\/j.biopha.2018.11.127.","DOI":"10.1016\/j.biopha.2018.11.127"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1045","article-title":"Artificial intelligence-assisted drug repurposing via \u201cchemical-induced gene expression ranking\u201d","volume":"3","author":"Masuda","year":"2022","journal-title":"Patterns (N Y)."},{"issue":"12","key":"10.1016\/j.intimp.2023.110331_b1050","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2589-7500(20)30192-8","article-title":"Artificial intelligence in COVID-19 drug repurposing","volume":"2","author":"Zhou","year":"2020","journal-title":"Lancet Digit Health."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b1055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.intimp.2023.110331_b1060","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1016\/j.csbj.2022.10.046","article-title":"Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles","volume":"9","author":"Ahmed","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.intimp.2023.110331_b1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100041","article-title":"Repurposing approved therapeutics for new indication: addressing unmet needs in psoriasis treatment","volume":"2","author":"Jain","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.intimp.2023.110331_b1070","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000500470","article-title":"Autophagy in Skin Diseases","volume":"235","author":"Guo","year":"2019","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b1075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/15548627.2020.1725381","article-title":"Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation","volume":"17","author":"Wang","year":"2021","journal-title":"Autophagy"},{"issue":"13","key":"10.1016\/j.intimp.2023.110331_b1080","article-title":"Autophagy and skin diseases","volume":"18","author":"Klapan","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1085","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1096\/fj.11-194175","article-title":"Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus","volume":"J.26","author":"Pierdominici","year":"2012","journal-title":"FASEB"},{"issue":"7","key":"10.1016\/j.intimp.2023.110331_b1090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00109-015-1297-8","article-title":"Autophagy in autoimmune disease","volume":"93","author":"Yang","year":"2015","journal-title":"J. Mol. Med. (Berl)"},{"issue":"7","key":"10.1016\/j.intimp.2023.110331_b1095","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jid.2016.03.016","article-title":"Constitutive autophagy and nucleophagy during epidermal differentiation","volume":"136","author":"Akinduro","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1100","first-page":"637","article-title":"Role of autophagy related Gene 16 L1 in psoriasis pathogenesis","volume":"31","author":"Naguib","year":"2021","journal-title":"J. Pak. Assoc. Dermatol."},{"issue":"15","key":"10.1016\/j.intimp.2023.110331_b1105","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.3390\/ijms22157869","article-title":"Potential therapeutic approaches through modulating the autophagy process for skin barrier dysfunction","volume":"22","author":"Choi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2023.110331_b1110","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.jid.2021.06.006","article-title":"Impaired autophagy in psoriasis and atopic dermatitis: a new therapeutic target?","volume":"141","author":"Hailfinger","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"15","key":"10.1016\/j.intimp.2023.110331_b1115","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2147\/CCID.S368105","article-title":"Effects of autophagy modulators and dioxin on the expression of epidermal differentiation proteins on psoriasis-like keratinocytes in vitro and ex vivo","volume":"23","author":"Kim","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b1120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/2475530318761399","article-title":"Vagus nerve stimulation: a novel anti-inflammatory treatment option for psoriasis and psoriatic arthritis?","volume":"3","author":"Yang","year":"2018","journal-title":"J. Psoriasis Psoriatic. Arthritis"},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b1125","doi-asserted-by":"crossref","first-page":"e13163","DOI":"10.1111\/nmo.13163","article-title":"Neuronal control of experimental colitis occurs via sympathetic intestinal innervation","volume":"30","author":"Willemze","year":"2018","journal-title":"Neurogastroenterol. Motil."},{"issue":"11","key":"10.1016\/j.intimp.2023.110331_b1130","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.4103\/jfmpc.jfmpc_709_19","article-title":"The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics","volume":"8","author":"Alesa","year":"2019","journal-title":"J. Family Med. Prim. Care."},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b1135","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/MIB.0000000000000750","article-title":"Current understanding of dysbiosis in disease in human and animal models","volume":"22","author":"DeGruttola","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"issue":"14","key":"10.1016\/j.intimp.2023.110331_b1140","first-page":"2970","volume":"14","author":"Buha\u0219","year":"2022","journal-title":"Gut Microbiota in Psoriasis. Nutrients"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1145","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/jocd.14273","article-title":"Psoriasis: Embarking a dynamic shift in the skin microbiota","volume":"21","author":"Gupta","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"issue":"272","key":"10.1016\/j.intimp.2023.110331_b1150","article-title":"Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice","volume":"23","author":"Li","year":"2021","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b1155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/diseases6020047","article-title":"Psoriasis and microbiota: a systematic review","volume":"6","author":"Benhadou","year":"2018","journal-title":"Diseases"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1160","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jocd.13752","article-title":"Skin microbiota as a therapeutic target for psoriasis treatment: trends and perspectives","volume":"20","author":"Rigon","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b1165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/096368910X","article-title":"Mesenchymal stem cells","volume":"20","author":"Ding","year":"2011","journal-title":"Cell Transplant."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b1170","doi-asserted-by":"crossref","first-page":"614","DOI":"10.5603\/FM.a2021.0076","article-title":"A potential role of mesenchymal stem cells derived from human umbilical cord blood in ameliorating psoriasis-like skin lesion in the rats","volume":"81","author":"Attia","year":"2021","journal-title":"Folia Morphol (Warsz)"},{"key":"10.1016\/j.intimp.2023.110331_b1175","first-page":"281","article-title":"Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice","volume":"9","author":"Lee","year":"2009","journal-title":"Biochem. Biophys. Rep."},{"issue":"23","key":"10.1016\/j.intimp.2023.110331_b1180","doi-asserted-by":"crossref","first-page":"6798","DOI":"10.12998\/wjcc.v9.i23.6798","article-title":"Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: a case report","volume":"9","author":"Ahn","year":"2021","journal-title":"World J. Clin. Cases"},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b1185","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-022-01059-y","article-title":"Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1\/2a, single-arm study","volume":"7","author":"Cheng","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b1190","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1002\/term.2423","article-title":"Tonsil-derived mesenchymal stem cells (T-MSCs) prevent Th17-mediated autoimmune response via regulation of the programmed death-1\/programmed death ligand-1 (PD-1\/PD-L1) pathway","volume":"12","author":"Kim","year":"2018","journal-title":"J. Tissue Eng. Regen. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b1195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/cei.13141","article-title":"Indirect co-cultures of healthy mesenchymal stem cells restore the physiological phenotypical profile of psoriatic mesenchymal stem cells","volume":"193","author":"Campanati","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.abd.2021.10.002","article-title":"Stem cell therapy as a potential treatment option for psoriasis","volume":"97","author":"Naik","year":"2022","journal-title":"An. Bras. Dermatol."},{"issue":"14","key":"10.1016\/j.intimp.2023.110331_b1205","doi-asserted-by":"crossref","first-page":"1092668","DOI":"10.3389\/fimmu.2023.1092668","article-title":"Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: atopic dermatitis and psoriasis","volume":"20","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100116","article-title":"The relapse of psoriasis: mechanisms and mysteries","volume":"2","author":"Tian","year":"2022","journal-title":"JID Innov."},{"key":"10.1016\/j.intimp.2023.110331_b1215","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","article-title":"Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences","volume":"9","author":"Boehncke","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b1220","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/biomedicines10020498","article-title":"Orchestrated cytokines mediated by biologics in psoriasis and its mechanisms of action","volume":"10","author":"Mohd Noor","year":"2022","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b1225","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/jcm12051801","article-title":"Gelsolin as a potential clinical biomarker in psoriasis vulgaris","volume":"12","author":"Lee","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2023.110331_b1230","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.2147\/JIR.S378953","article-title":"Fibrinogen-like protein 1 as a novel biomarker of psoriasis severity","volume":"15","author":"Sun","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1235","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/ijd.ijd_570_22","article-title":"Psoriasis in pediatric age group","volume":"67","author":"Dhar","year":"2022","journal-title":"Indian J. Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2023.110331_b1240","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s13555-022-00811-0","article-title":"Unmet need in people with psoriasis and skin of color in canada and the united states","volume":"12","author":"Yadav","year":"2022","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"2","key":"10.1016\/j.intimp.2023.110331_b1245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13555-021-00677-8","article-title":"Role of interleukin 36 in generalised pustular psoriasis and beyond","volume":"12","author":"Sugiura","year":"2022","journal-title":"Dermatol. Ther. (Heidelb)"},{"issue":"82","key":"10.1016\/j.intimp.2023.110331_b1250","article-title":"Treatment of generalized pustular psoriasis in pregnancy with systemic corticosteroid: a rare case report","volume":"10","author":"Isse Ali","year":"2022","journal-title":"Ann. Med. Surg. (Lond)"},{"issue":"8","key":"10.1016\/j.intimp.2023.110331_b1255","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/medicina57080804","article-title":"State-of-the-art review of pregnancy-related psoriasis","volume":"57","author":"Simionescu","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.intimp.2023.110331_b1260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.47102\/annals-acadmedsg.2021380","article-title":"Novel transdermal device for delivery of triamcinolone for nail psoriasis treatment","volume":"51","author":"Yew","year":"2022","journal-title":"Ann. Acad. Med. Singap."},{"issue":"8 Suppl","key":"10.1016\/j.intimp.2023.110331_b1265","first-page":"238","article-title":"Managed care aspects of psoriasis and psoriatic arthritis","volume":"22","author":"Evans","year":"2016","journal-title":"Am. J. Manag. Care"},{"issue":"4","key":"10.1016\/j.intimp.2023.110331_b1270","first-page":"501","article-title":"Biomarkers in oral fluids as diagnostic tool for psoriasis","volume":"12","author":"Jim\u00e9nez","year":"2022","journal-title":"Life (Basel)"},{"issue":"19","key":"10.1016\/j.intimp.2023.110331_b1275","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.3390\/molecules27196640","article-title":"S100 proteins as novel therapeutic targets in psoriasis and other autoimmune diseases","volume":"27","author":"Kurpet","year":"2022","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.intimp.2023.110331_b1280","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjd.20940","article-title":"Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis","volume":"186","author":"Luengas-Martinez","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110331_b1285","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/jpm12060978","article-title":"Role of yes-associated protein in psoriasis and skin tumor pathogenesis","volume":"12","author":"Jia","year":"2022","journal-title":"J Pers Med."},{"key":"10.1016\/j.intimp.2023.110331_b1290","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.850967","article-title":"ANGPTL4 regulates psoriasis via modulating hyperproliferation and inflammation of keratinocytes","volume":"13","author":"Zuo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2023.110331_b1295","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.semcdb.2021.06.018","article-title":"Keratin 17 in psoriasis: current understanding and future perspectives","volume":"128","author":"Lin","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110331_b1300","doi-asserted-by":"crossref","first-page":"e13290","DOI":"10.1111\/cpr.13290","article-title":"Sprouty1 exerts a preventive effect on the initiation of psoriasis by inhibiting innate immune antimicrobial peptide cathelicidin and immunocytes","volume":"55","author":"Zhou","year":"2022","journal-title":"Cell Prolif."},{"issue":"3","key":"10.1016\/j.intimp.2023.110331_b1305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ad.2022.08.023","article-title":"Telocytes in cutaneous biology: a reappraisal","volume":"114","author":"Ahmed","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.intimp.2023.110331_b1310","doi-asserted-by":"crossref","first-page":"1017126","DOI":"10.3389\/fmed.2022.1017126","article-title":"Exploration of and insights into advanced topical nanocarrier systems for the treatment of psoriasis","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med. (Lausanne)"},{"key":"10.1016\/j.intimp.2023.110331_b1315","doi-asserted-by":"crossref","unstructured":"T.S. Patil, N.A. Gujarathi, A.A. Aher, H.E. Pachpande, C. Sharma, S. Ojha, S.N. Goyal, Y.O. Agrawal, Recent Advancements in Topical Anti-Psoriatic Nanostructured Lipid Carrier-Based Drug Delivery, Int J Mol Sci. 24 (3) 9 (2023) 2978. doi: 10.3390\/ijms24032978.","DOI":"10.3390\/ijms24032978"},{"key":"10.1016\/j.intimp.2023.110331_b1320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122535","article-title":"Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis","volume":"631","author":"Gomes","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"17","key":"10.1016\/j.intimp.2023.110331_b1325","doi-asserted-by":"crossref","first-page":"9845","DOI":"10.3390\/ijms23179845","article-title":"An update on photodynamic therapy of psoriasis-current strategies and nanotechnology as a future perspective","volume":"23","author":"Makuch","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:59:17Z","timestamp":1761587957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923006549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":265,"alternative-id":["S1567576923006549"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110331","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging prospects in the psoriatic treatment","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110331"}}